ワクチン市場 : 2028年までの世界予測

Report Overview

The global vaccines market size is projected to reach USD 93.8 billion by 2028 from USD 77.6 billion in 2023, at a CAGR of 3.9% during the forecast period. Factors such as high incidence of contagious diseases, innovation in vaccine technology, governmental support & substantial funding for vaccine development, growing vaccination initiatives and strong focus on investing and launching innovative vaccines.

“The conjugate vaccines segment held the dominant share in the vaccines market”
Based on technology, the global vaccines market is segmented into inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, viral vector vaccines, recombinant vaccines and conjugate vaccines. The conjugate vaccines segment  is anticipated to grow at significant CAGR. Growing governmental support coupled with investment by companies in the field of conjugate vaccine development, increasing collaboration between public and private sectors are likely to have positive impact on the growth of the market.

“Pneumococcal segment accounted for the largest share of the disease indication segment in 2022.”
Based on disease indication, the vaccines market is segmented into, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, and other disease indications. In 2022, the pneumococcal segment accounted for the largest share of the vaccines market. The segment held the dominant share in the market owing to various factors such increased pneumococcal disease cases, with a rising government investment in vaccination programs.

“Asia Pacific region is likely to grow at a faster pace in the vaccines market.”
The vaccines market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by companies that are upping their investments in Asia-Pacific region, benefiting from increased government support for vaccine development, rising healthcare expenditure in Asian countries, emergence & re-emergence of contagious disease and rising disposable income.

The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 80%, and Demand Side – 20%
• By Designation (Supply Side): Managers – 45%, CXOs & Directors – 30%, Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East-4%  and Africa -1

List of Companies Profiled in the Report:
• GSK plc (UK)
• Merck & Co., Inc. (US)
• Pfizer, Inc. (US)
• Sanofi (France)
• CSL (Australia)
• Emergent (US)
• Johnson & Johnson Services Inc. (US)
• AstraZeneca (UK)
• Serum Institute of India Pvt. Ltd. (India)
• Bavarian Nordic (Denmark)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Daiichi Sankyo Company, Limited (Japan)
• Panacea Biotec (India)
• Biological E. Limited (India)
• Bharat Biotech (India)
• Novavax (US)
• Inovio Pharmaceuticals (US)
• Sinovac (China)
• Incepta Pharmaceuticals (Bangladesh)
• Valneva SE (France),
• VBI Vaccines Inc. (US)
• Bio Farma (Indonesia)
• FSUE NPO Microgen (Russia)
• Zhi fei Biological (China)
• Indian Immunologicals Ltd (India)

Research Coverage:
This report provides a detailed picture of the vaccines market. It aims at estimating the size and future growth potential of the market across different segments such as the technology, type, disease indication, route of administration, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccines market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:
• Analysis of key drivers (strong emphasis on investment and launch of novel vaccines, rising prevalence of infectious disease, expanding immunization programs, advancements in vaccine technology and robust government support & funding for the development of vaccines), restraints (High development cost, patent expiry ), opportunities (Increased focus on therapeutic vaccines, robust & strong pipeline) and challenges (stringnent regulatory processes, vaccine supply shortage, frequent product recall) are influencing the growth of clinical trial supplies market.
• Product Development/Innovation: Detailed insights on newly launched products of the vaccines market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the vaccines market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the vaccines market.
• Pipeline Analysis: Comprehensive information about products under clinical trials.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark).

Table of Contents

1            INTRODUCTION            44

1.1         STUDY OBJECTIVES      44

1.2         MARKET DEFINITION   44

1.3         INCLUSIONS & EXCLUSIONS     45

1.4         MARKET SCOPE             45

1.4.1      MARKETS COVERED     45

1.4.2      REGIONS COVERED      46

1.4.3      YEARS CONSIDERED     46

1.4.4      CURRENCY CONSIDERED          46

1.5         RESEARCH LIMITATIONS           47

1.6         STAKEHOLDERS            47

1.7         SUMMARY OF CHANGES            48

1.8         RECESSION IMPACT: VACCINES MARKET           48

2            RESEARCH METHODOLOGY     49

2.1         RESEARCH DATA           49

2.2         RESEARCH APPROACH 49

FIGURE 1           RESEARCH DESIGN       49

2.2.1      SECONDARY DATA       50

2.2.2      PRIMARY DATA 51

FIGURE 2           BREAKDOWN OF PRIMARIES     51

2.2.2.1   Primary insights   52

FIGURE 3           KEY INSIGHTS FROM PRIMARY EXPERTS            52

2.3         MARKET SIZE ESTIMATION       53

FIGURE 4           MARKET SIZE ESTIMATION: VACCINES MARKET, 2022   53

FIGURE 5           TOTAL REVENUE: VACCINES MARKET  54

FIGURE 6           REVENUE SHARE OF PFIZER INC., 2022  54

2.3.1      SEGMENTAL ASSESSMENT        55

FIGURE 7           TOP-DOWN APPROACH             55

2.4         GROWTH RATE ASSUMPTIONS 57

FIGURE 8           CAGR PROJECTION: VACCINES MARKET            57

FIGURE 9           GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES  58

2.5         STUDY ASSUMPTIONS  58

2.6         MARKET BREAKDOWN AND DATA TRIANGULATION    59

FIGURE 10         DATA TRIANGULATION METHODOLOGY         59

2.7         RISK ASSESSMENT         60

2.8         IMPACT OF RECESSION IN VACCINES MARKET 60

TABLE 1             GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH)         61

TABLE 2             US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)  61

TABLE 3             US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)  61

3            EXECUTIVE SUMMARY 62

FIGURE 11         VACCINES MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)           62

FIGURE 12         VACCINES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION)              63

FIGURE 13         VACCINES MARKET, BY DISEASE INDICATION, 2023 VS. 2028 (USD BILLION) 64

FIGURE 14         VACCINES MARKET, BY ROUTE OF ADMINISTRATION,  2023 VS. 2028 (USD BILLION) 65

FIGURE 15         VACCINES MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)              65

FIGURE 16         GEOGRAPHICAL SNAPSHOT OF VACCINES MARKET     66

4            PREMIUM INSIGHTS      68

4.1         VACCINES MARKET OVERVIEW 68

FIGURE 17         RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET            68

4.2         NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY  AND COUNTRY, 2022 69

FIGURE 18         M-RNA VACCINES AND US ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN VACCINES MARKET IN 2022        69

4.3         VACCINES MARKET, BY TECHNOLOGY, 2023 VS. 2028    70

FIGURE 19         M-RNA VACCINES TO DOMINATE MARKET IN 2028        70

4.4         GEOGRAPHICAL GROWTH OPPORTUNITIES: VACCINES MARKET              70

FIGURE 20         ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD       70

5            MARKET OVERVIEW     71

5.1         INTRODUCTION            71

5.2         MARKET DYNAMICS     71

FIGURE 21         DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: VACCINES MARKET       71

TABLE 4             IMPACT ANALYSIS: VACCINES MARKET 72

5.2.1      DRIVERS            72

5.2.1.1   Strong emphasis on launch of novel vaccines  72

5.2.1.2   Rising prevalence of infectious diseases         73

FIGURE 22         INCIDENCE OF TUBERCULOSIS IN US, 2017–2021            74

5.2.1.3   Increasing number of immunization programs             74

5.2.1.4   Advancements in vaccine technology             75

5.2.1.5   Robust government support and funding for vaccine development           75

TABLE 5             NIH FUNDING FOR VACCINE RESEARCH, 2020–2024 (USD MILLION)          76

5.2.2      RESTRAINTS     76

5.2.2.1   High cost of vaccine development    76

5.2.3      OPPORTUNITIES           77

5.2.3.1   Increased focus on therapeutic vaccines         77

5.2.3.2   Extensive R&D for vaccines and increased investments in clinical trials    77

5.2.4      CHALLENGES   78

5.2.4.1   Stringent regulatory processes         78

5.2.4.2   Frequent product recalls    78

5.3         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 79

FIGURE 23         REVENUE SHIFTS AND NEW REVENUE POCKETS FOR VACCINE PROVIDERS       79

5.4         PRICING ANALYSIS        79

5.4.1      AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYERS       79

TABLE 6             AVERAGE SELLING PRICE OF PEDIATRIC VACCINES      79

TABLE 7             AVERAGE SELLING PRICE OF ADULT VACCINES             81

5.4.2      AVERAGE SELLING PRICE, BY PRODUCT TYPE  82

TABLE 8             AVERAGE SELLING PRICE OF CONJUGATE VACCINES   82

TABLE 9             AVERAGE SELLING PRICE OF RECOMBINANT VACCINES              82

TABLE 10           AVERAGE SELLING PRICE OF INACTIVATED & SUBUNIT VACCINES         83

TABLE 11           AVERAGE SELLING PRICE OF LIVE ATTENUTAED VACCINES              83

TABLE 12           AVERAGE SELLING PRICE OF TOXOID VACCINES           84

TABLE 13           AVERAGE SELLING PRICE OF M-RNA VACCINES              84

5.4.3      AVERAGE SELLING PRICE TREND          85

5.5         TECHNOLOGY ANALYSIS           85

5.6         VALUE CHAIN ANALYSIS            85

FIGURE 24         VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES TO CONTRIBUTE MAXIMUM VALUE             86

5.7         PIPELINE ANALYSIS      87

FIGURE 25         CLINICAL TRIALS IN VACCINES MARKET            87

FIGURE 26         VACCINES MARKET IN CLINICAL TRIALS, BY DISEASE INDICATION     87

TABLE 14           PIPELINE PRODUCTS UNDER PHASE-2 AND PHASE-3 CLINICAL TRIALS 88

5.7.1      KEY PIPELINE PRODUCTS         91

TABLE 15           KEY PIPELINE VACCINES: GSK PL           91

TABLE 16           KEY PIPELINE VACCINES: MERCK & CO., INC.     91

TABLE 17           KEY PIPELINE VACCINES: PFIZER, INC.  91

TABLE 18           KEY PIPELINE VACCINES: SANOFI S.A.   91

5.8         ECOSYSTEM MARKET/MAP       92

FIGURE 27         ECOSYSTEM MARKET/MAP       92

TABLE 19           ROLE IN ECOSYSTEM: VACCINES MARKET         92

5.9         REGULATORY ANALYSIS            93

5.9.1      REGULATORY LANDSCAPE FOR VACCINES        93

5.9.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          95

TABLE 20           NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         95

TABLE 21           EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96

TABLE 22           ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         97

TABLE 23           LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         97

TABLE 24           MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         98

TABLE 25           AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98

5.10       PORTER’S FIVE FORCES ANALYSIS         98

TABLE 26           PORTER’S FIVE FORCES ANALYSIS         98

5.10.1    THREAT OF NEW ENTRANTS    99

5.10.2    THREAT OF SUBSTITUTES         99

5.10.3    BARGAINING POWER OF SUPPLIERS     99

5.10.4    BARGAINING POWER OF BUYERS           99

5.10.5    INTENSITY OF COMPETITIVE RIVALRY 99

5.11       PATENT ANALYSIS        100

FIGURE 28         PATENT APPLICATIONS FOR VACCINES, SEPTEMBER 2013–SEPTEMBER 2023           100

TABLE 27           INDICATIVE LIST OF PATENTS IN VACCINES MARKET  100

5.12       KEY CONFERENCES & EVENTS  101

TABLE 28           DETAILED LIST OF KEY CONFERENCES & EVENTS, 2023–2024              101

5.13       KEY STAKEHOLDERS & BUYING CRITERIA          102

5.13.1    KEY STAKEHOLDERS IN BUYING PROCESS         102

FIGURE 29         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES         102

5.13.2    KEY BUYING CRITERIA 103

FIGURE 30         KEY BUYING CRITERIA FOR END USERS IN VACCINES MARKET              103

6            VACCINES MARKET, BY TECHNOLOGY 104

6.1         INTRODUCTION            105

TABLE 29           VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)           105

6.2         CONJUGATE VACCINES 105

6.2.1      INCREASING PUBLIC-PRIVATE PARTNERSHIPS TO DRIVE MARKET              105

TABLE 30           VACCINES MARKET FOR CONJUGATE VACCINES, BY REGION, 2021–2028 (USD BILLION)           106

TABLE 31           NORTH AMERICA: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    107

TABLE 32           EUROPE: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)  107

TABLE 33          ASIA PACIFIC: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)          108

TABLE 34           LATIN AMERICA: VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    108

6.3         RECOMBINANT VACCINES        108

6.3.1      LESSER POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES TO DRIVE MARKET    108

TABLE 35           EXAMPLES OF RECOMBINANT VACCINES          109

TABLE 36           VACCINES MARKET FOR RECOMBINANT VACCINES, BY REGION,  2021–2028 (USD BILLION)      110

TABLE 37           NORTH AMERICA: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)       110

TABLE 38           EUROPE: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)          111

TABLE 39           ASIA PACIFIC: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    111

TABLE 40           LATIN AMERICA: VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    112

6.4         INACTIVATED & SUBUNIT VACCINES    112

6.4.1      EASE OF STORAGE AND TRANSPORTATION TO DRIVE MARKET              112

TABLE 41           EXAMPLES OF INACTIVATED & SUBUNIT VACCINES      113

TABLE 42           VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY REGION,  2021–2028 (USD BILLION) 114

TABLE 43           NORTH AMERICA: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES,  BY COUNTRY, 2021–2028 (USD BILLION) 114

TABLE 44           EUROPE: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)       115

TABLE 45           ASIA PACIFIC: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)   115

TABLE 46           LATIN AMERICA: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES,  BY COUNTRY, 2021–2028 (USD BILLION) 116

6.5         LIVE ATTENUATED VACCINES 116

6.5.1      HIGH COST OF STORAGE AND LIMITED FINANCIAL RESOURCES OF DISTRIBUTORS TO LIMIT MARKET        116

TABLE 47           EXAMPLES OF LIVE ATTENUATED VACCINES   117

TABLE 48           VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION,  2021–2028 (USD BILLION)      117

TABLE 49           NORTH AMERICA: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)        118

TABLE 50           EUROPE: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    118

TABLE 51           ASIA PACIFIC: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    119

TABLE 52           LATIN AMERICA: VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)       119

6.6         TOXOID VACCINES       119

6.6.1      RISING PREVALENCE OF BACTERIAL INFECTIONS AMONG INFANTS AND CHILDREN TO DRIVE MARKET      119

TABLE 53           EXAMPLES OF TOXOID VACCINES         120

TABLE 54           VACCINES MARKET FOR TOXOID VACCINES, BY REGION, 2021–2028 (USD BILLION)      120

TABLE 55          NORTH AMERICA: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)          121

TABLE 56           EUROPE: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)  121

TABLE 57           ASIA PACIFIC: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)  122

TABLE 58           LATIN AMERICA: VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)          122

6.7         VIRAL VECTOR VACCINES         123

6.7.1      INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET 123

TABLE 59           VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY REGION,  2021–2028 (USD BILLION)      123

TABLE 60           NORTH AMERICA: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)       124

TABLE 61           EUROPE: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)          124

TABLE 62           ASIA PACIFIC: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    125

TABLE 63           LATIN AMERICA: VACCINES MARKET FOR VIRAL VECTOR VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    125

6.8         M-RNA VACCINES          126

6.8.1      INCREASING INVESTMENT IN M-RNA VACCINE DEVELOPMENT TO DRIVE MARKET 126

TABLE 64           VACCINES MARKET FOR M-RNA VACCINES, BY REGION, 2021–2028 (USD BILLION)      127

TABLE 65           NORTH AMERICA: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)          127

TABLE 66           EUROPE: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)  128

TABLE 67           ASIA PACIFIC: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)  128

TABLE 68           LATIN AMERICA: VACCINES MARKET FOR M-RNA VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)          129

6.9         OTHER VACCINES         129

TABLE 69           VACCINES MARKET FOR OTHER VACCINES, BY REGION, 2021–2028 (USD BILLION)      130

TABLE 70           NORTH AMERICA: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)          130

TABLE 71           EUROPE: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)  131

TABLE 72           ASIA PACIFIC: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)  131

TABLE 73           LATIN AMERICA: VACCINES MARKET FOR OTHER VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)          132

7            VACCINES MARKET, BY TYPE    133

7.1         INTRODUCTION            134

TABLE 74           VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)              134

7.2         MONOVALENT VACCINES         134

7.2.1      INCREASING INVESTMENT IN R&D AND RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET        134

TABLE 75           EXAMPLES OF MONOVALENT VACCINES           135

TABLE 76           VACCINES MARKET FOR MONOVALENT VACCINES, BY REGION,  2021–2028 (USD BILLION)      136

TABLE 77           NORTH AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    136

TABLE 78           EUROPE: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)          137

TABLE 79           ASIA PACIFIC: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    137

TABLE 80           LATIN AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    138

7.3         MULTIVALENT VACCINES         138

7.3.1      INCREASED NEED FOR IMMUNIZATION AND COST-EFFECTIVENESS TO DRIVE MARKET       138

TABLE 81           EXAMPLES OF MULTIVALENT VACCINES           139

TABLE 82           VACCINES MARKET FOR MULTIVALENT VACCINES, BY REGION,  2021–2028 (USD BILLION)      140

TABLE 83           NORTH AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    140

TABLE 84           EUROPE: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)          141

TABLE 85           ASIA PACIFIC: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    141

TABLE 86           LATIN AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    142

8            VACCINES MARKET, BY DISEASE INDICATION  143

8.1         INTRODUCTION            144

TABLE 87           VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)           144

8.2         PNEUMOCOCCAL DISEASE        144

8.2.1      INCREASING INCIDENCE OF PNEUMONIA IN CHILDREN TO DRIVE MARKET            144

TABLE 88           LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES       145

TABLE 89           VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION,  2021–2028 (USD BILLION)      146

TABLE 90           NORTH AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION)          146

TABLE 91           EUROPE: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY,  2021–2028 (USD BILLION)          147

TABLE 92           ASIA PACIFIC: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY,  2021–2028 (USD BILLION)       147

TABLE 93           LATIN AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION)          148

8.3         INFLUENZA      148

8.3.1      RISING NEED FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET 148

TABLE 94           LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES              149

TABLE 95           VACCINES MARKET FOR INFLUENZA, BY REGION, 2021–2028 (USD BILLION) 150

TABLE 96           NORTH AMERICA: VACCINES MARKET FOR INFLUENZA, BY COUNTRY,  2021–2028 (USD BILLION)  150

TABLE 97           EUROPE: VACCINES MARKET FOR INFLUENZA, BY COUNTRY,  2021–2028 (USD BILLION)           151

TABLE 98           ASIA PACIFIC: VACCINES MARKET FOR INFLUENZA, BY COUNTRY,  2021–2028 (USD BILLION)  151

TABLE 99           LATIN AMERICA: VACCINES MARKET FOR INFLUENZA, BY COUNTRY,  2021–2028 (USD BILLION)  152

8.4         COMBINATION VACCINES         152

8.4.1      GROWING DEMAND FOR ALL-IN-ONE VACCINE TO DRIVE MARKET              152

TABLE 100         LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES         153

TABLE 101         VACCINES MARKET FOR COMBINATION VACCINES, BY REGION,  2021–2028 (USD BILLION)      154

TABLE 102         NORTH AMERICA: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY, 2021–2028 (USD BILLION)       154

TABLE 103         EUROPE: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)          155

TABLE 104         ASIA PACIFIC: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    155

TABLE 105         LATIN AMERICA: VACCINES MARKET FOR COMBINATION VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    156

8.5         HPV      156

8.5.1      GROWING INCIDENCE OF SEXUALLY TRANSMITTED DISEASES TO DRIVE MARKET 156

TABLE 106         LIST OF COMMERCIALLY AVAILABLE HPV VACCINES   157

TABLE 107         VACCINES MARKET FOR HPV, BY REGION, 2021–2028 (USD BILLION)           158

TABLE 108         NORTH AMERICA: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION)           158

TABLE 109         EUROPE: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION)      159

TABLE 110         ASIA PACIFIC: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION)           159

TABLE 111         LATIN AMERICA: VACCINES MARKET FOR HPV, BY COUNTRY, 2021–2028 (USD BILLION)           160

8.6         MENINGOCOCCAL DISEASE      160

8.6.1      INCREASING INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS TO DRIVE MARKET   160

TABLE 112         LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES       161

TABLE 113         VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION,  2021–2028 (USD BILLION)      161

TABLE 114         NORTH AMERICA: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION)          162

TABLE 115         EUROPE: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY,  2021–2028 (USD BILLION)          162

TABLE 116         ASIA PACIFIC: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY,  2021–2028 (USD BILLION)       163

TABLE 117         LATIN AMERICA: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021–2028 (USD BILLION)          163

8.7         HERPES ZOSTER            163

8.7.1      INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET 163

TABLE 118         VACCINES MARKET FOR HERPES ZOSTER, BY REGION, 2021–2028 (USD BILLION)      164

TABLE 119         NORTH AMERICA: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY,  2021–2028 (USD BILLION)          165

TABLE 120         EUROPE: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY,  2021–2028 (USD BILLION)  165

TABLE 121         ASIA PACIFIC: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY,  2021–2028 (USD BILLION)  166

TABLE 122         LATIN AMERICA: VACCINES MARKET FOR HERPES ZOSTER, BY COUNTRY,  2021–2028 (USD BILLION)  166

8.8         ROTAVIRUS      166

8.8.1      GROWING FOCUS OF GOVERNMENT AND NON-GOVERNMENT BODIES ON ROTAVIRUS PREVENTION TO DRIVE MARKET         166

TABLE 123         LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES              167

TABLE 124         VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2021–2028 (USD BILLION) 167

TABLE 125         NORTH AMERICA: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY,  2021–2028 (USD BILLION)  168

TABLE 126         EUROPE: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021–2028 (USD BILLION)           168

TABLE 127         ASIA PACIFIC: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY,  2021–2028 (USD BILLION)  169

TABLE 128         LATIN AMERICA: VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY,  2021–2028 (USD BILLION)  169

8.9         MMR     170

8.9.1      RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA TO DRIVE MARKET            170

TABLE 129         LIST OF COMMERCIALLY AVAILABLE MMR VACCINES  170

TABLE 130         VACCINES MARKET FOR MMR, BY REGION, 2021–2028 (USD BILLION)           171

TABLE 131         NORTH AMERICA: VACCINES MARKET FOR MMR, BY COUNTRY,  2021–2028 (USD BILLION)  171

TABLE 132         EUROPE: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION)      172

TABLE 133         ASIA PACIFIC: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION)           172

TABLE 134         LATIN AMERICA: VACCINES MARKET FOR MMR, BY COUNTRY, 2021–2028 (USD BILLION)           173

8.10       VARICELLA       173

8.10.1    INCREASING PROMOTION OF IMMUNIZATION PROGRAMS TO DRIVE MARKET            173

TABLE 135         LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES              173

TABLE 136         VACCINES MARKET FOR VARICELLA, BY REGION, 2021–2028 (USD BILLION) 174

TABLE 137         NORTH AMERICA: VACCINES MARKET FOR VARICELLA, BY COUNTRY,  2021–2028 (USD BILLION)  174

TABLE 138         EUROPE: VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021–2028 (USD BILLION)           175

TABLE 139         ASIA PACIFIC: VACCINES MARKET FOR VARICELLA, BY COUNTRY,  2021–2028 (USD BILLION)  175

TABLE 140         LATIN AMERICA: VACCINES MARKET FOR VARICELLA, BY COUNTRY,  2021–2028 (USD BILLION)  176

8.11       HEPATITIS        176

8.11.1    LOW SOCIO-ECONOMIC STANDARDS OF LIVING AND HIGH CONTAMINATION IN DRINKING WATER TO DRIVE MARKET     176

TABLE 141         LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES              177

TABLE 142         VACCINES MARKET FOR HEPATITIS, BY REGION, 2021–2028 (USD MILLION) 177

TABLE 143         NORTH AMERICA: VACCINES MARKET FOR HEPATITIS, BY COUNTRY,  2021–2028 (USD BILLION)  178

TABLE 144         EUROPE: VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION)           178

TABLE 145         ASIA PACIFIC: VACCINES MARKET FOR HEPATITIS, BY COUNTRY,  2021–2028 (USD BILLION)  179

TABLE 146         LATIN AMERICA: VACCINES MARKET FOR HEPATITIS, BY COUNTRY,  2021–2028 (USD BILLION)  179

8.12       DTP      180

8.12.1    INCREASED OCCURRENCE OF DIPHTHERIA, TETANUS, AND PERTUSSIS IN EMERGING ECONOMIES TO DRIVE MARKET        180

TABLE 147         LIST OF COMMERCIALLY AVAILABLE DTP VACCINES   180

TABLE 148         VACCINES MARKET FOR DTP, BY REGION, 2021–2028 (USD BILLION)           181

TABLE 149         NORTH AMERICA: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION)           181

TABLE 150         EUROPE: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION)      182

TABLE 151         ASIA PACIFIC: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION)           182

TABLE 152         LATIN AMERICA: VACCINES MARKET FOR DTP, BY COUNTRY, 2021–2028 (USD BILLION)           183

8.13       POLIO  183

8.13.1    INCREASING GOVERNMENT INITIATIVES AND IMMUNIZATION PROGRAMS TO DRIVE MARKET 183

TABLE 153         VACCINES MARKET FOR POLIO, BY REGION, 2021–2028 (USD BILLION)           184

TABLE 154         NORTH AMERICA: VACCINES MARKET FOR POLIO, BY COUNTRY,  2021–2028 (USD BILLION)  185

TABLE 155         EUROPE: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION)      185

TABLE 156         ASIA PACIFIC: VACCINES MARKET FOR POLIO, BY COUNTRY, 2021–2028 (USD BILLION)           186

TABLE 157         LATIN AMERICA: VACCINES MARKET FOR POLIO, BY COUNTRY,  2021–2028 (USD BILLION)  186

8.14       OTHER DISEASE INDICATIONS 186

FIGURE 31         NUMBER OF COVID-19 CASES IN US, 2020–2023 187

TABLE 158         LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS 187

TABLE 159         VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION,  2021–2028 (USD BILLION)      188

TABLE 160         NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION) 188

TABLE 161         EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY,  2021–2028 (USD BILLION)            189

TABLE 162         ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION) 189

TABLE 163         LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD BILLION) 190

9            VACCINES MARKET, BY ROUTE OF ADMINISTRATION  191

9.1         INTRODUCTION            192

TABLE 164         VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)      192

9.2         INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION     192

9.2.1      EASIER ABSORPTION INTO BLOODSTREAM AND BETTER IMMUNE RESPONSE TO DRIVE MARKET 192

TABLE 165         ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION          193

TABLE 166         VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION,  BY REGION, 2021–2028 (USD BILLION)              194

TABLE 167         NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)           194

TABLE 168         EUROPE: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)              195

TABLE 169         ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)              195

TABLE 170         LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)           196

9.3         ORAL ADMINISTRATION            196

9.3.1      EASE OF ADMINISTRATION AND REDUCED RISK OF BLOOD-TRANSMITTED INFECTIONS TO DRIVE MARKET            196

TABLE 171         VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION, 2021–2028 (USD BILLION)           197

TABLE 172         NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY,  2021–2028 (USD BILLION)   197

TABLE 173         EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY,  2021–2028 (USD BILLION)  198

TABLE 174         ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY,  2021–2028 (USD BILLION)   198

TABLE 175         LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION, BY COUNTRY,  2021–2028 (USD BILLION)   199

9.4         OTHER ROUTES OF ADMINISTRATION 199

TABLE 176         VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION,  2021–2028 (USD BILLION)       200

TABLE 177         NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION,  BY COUNTRY, 2021–2028 (USD BILLION)           200

TABLE 178         EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD BILLION)      201

TABLE 179         ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION,  BY COUNTRY, 2021–2028 (USD BILLION)   201

TABLE 180         LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION,  BY COUNTRY, 2021–2028 (USD BILLION)   202

10          VACCINES MARKET, BY END USER         203

10.1       INTRODUCTION            204

TABLE 181         VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)              204

10.2       PEDIATRIC VACCINES  204

10.2.1    INCREASED INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT BODIES TO DRIVE MARKET       204

TABLE 182         VACCINES MARKET FOR PEDIATRIC VACCINES, BY REGION, 2021–2028 (USD BILLION)           205

TABLE 183         NORTH AMERICA: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    206

TABLE 184         EUROPE: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)  206

TABLE 185         ASIA PACIFIC: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)          207

TABLE 186         LATIN AMERICA: VACCINES MARKET FOR PEDIATRIC VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)    207

10.3       ADULT VACCINES         207

10.3.1    ADULT VACCINES SEGMENT TO COMMAND LARGER MARKET SHARE DURING FORECAST PERIOD     207

TABLE 187         VACCINES MARKET FOR ADULT VACCINES, BY REGION, 2021–2028 (USD BILLION)      209

TABLE 188         NORTH AMERICA: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)          209

TABLE 189         EUROPE: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)  210

TABLE 190         ASIA PACIFIC: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)  210

TABLE 191         LATIN AMERICA: VACCINES MARKET FOR ADULT VACCINES, BY COUNTRY,  2021–2028 (USD BILLION)          211

11          VACCINES MARKET, BY REGION             212

11.1       INTRODUCTION            213

TABLE 192         VACCINES MARKET, BY REGION, 2021–2028 (USD BILLION)              213

11.2       NORTH AMERICA          213

FIGURE 32         NORTH AMERICA: VACCINES MARKET SNAPSHOT         214

TABLE 193         NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)      215

TABLE 194         NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)           215

TABLE 195         NORTH AMERICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 216

TABLE 196         NORTH AMERICA: VACCINES MARKET, BY DISEASE INDICATION,  2021–2028 (USD BILLION)            216

TABLE 197         NORTH AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD BILLION) 217

TABLE 198         NORTH AMERICA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)      217

11.3       NORTH AMERICA: RECESSION IMPACT 217

11.3.1    US         218

11.3.1.1 US to dominate North American vaccines market during forecast period 218

TABLE 199         US: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)           219

TABLE 200         US: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)              219

TABLE 201         US: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 220

TABLE 202         US: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)           220

TABLE 203         US: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           221

11.3.2    CANADA            221

11.3.2.1 High incidence of infectious diseases to drive market   221

TABLE 204         CANADA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 222

TABLE 205         CANADA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)           222

TABLE 206         CANADA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)      223

TABLE 207         CANADA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD BILLION) 223

TABLE 208         CANADA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           224

11.4       EUROPE             224

TABLE 209         EUROPE: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)           224

TABLE 210         EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 225

TABLE 211         EUROPE: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)           225

TABLE 212         EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)      226

TABLE 213        EUROPE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)           226

TABLE 214         EUROPE: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           227

11.5       EUROPE: RECESSION IMPACT   227

11.5.1    GERMANY         227

11.5.1.1 Significant R&D investments and growing biotechnology industry to drive market              227

TABLE 215         GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 229

TABLE 216         GERMANY: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)           229

TABLE 217         GERMANY: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)           230

TABLE 218         GERMANY: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD BILLION) 230

TABLE 219         GERMANY: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           231

11.5.2    UK         231

11.5.2.1 Launch of new products and increased funding by government and non-government organizations to drive market     231

TABLE 220         UK: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)           232

TABLE 221         UK: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)              232

TABLE 222         UK: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION) 233

TABLE 223         UK: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)           233

TABLE 224         UK: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           234

11.5.3    FRANCE             234

11.5.3.1 Favorable government initiatives for mass immunization to drive market 234

TABLE 225         FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 235

TABLE 226         FRANCE: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)           235

TABLE 227         FRANCE: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)      236

TABLE 228        FRANCE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD BILLION)           236

TABLE 229         FRANCE: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           237

11.5.4    ITALY   237

11.5.4.1 Higher investments by companies for increased production capacities to drive market   237

TABLE 230         ITALY: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)           238

TABLE 231         ITALY: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)              238

TABLE 232         ITALY: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)      239

TABLE 233         TALY: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)           239

TABLE 234         ITALY: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           240

11.5.5    SPAIN   240

11.5.5.1 Rising investments in vaccine development by private organizations to drive market   240

TABLE 235         SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)           241

TABLE 236         SPAIN: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)              241

TABLE 237         SPAIN: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)      242

TABLE 238         SPAIN: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)           242

TABLE 239         SPAIN: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           243

11.5.6    REST OF EUROPE           243

TABLE 240         REST OF EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)           244

TABLE 241         REST OF EUROPE: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 244

TABLE 242         REST OF EUROPE: VACCINES MARKET, BY DISEASE INDICATION,  2021–2028 (USD BILLION)            245

TABLE 243         REST OF EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD BILLION) 245

TABLE 244         REST OF EUROPE: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 246

11.6       ASIA PACIFIC    246

FIGURE 33         ASIA PACIFIC: VACCINES MARKET SNAPSHOT  247

TABLE 245         ASIA PACIFIC: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 248

TABLE 246         ASIA PACIFIC: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)      248

TABLE 247         ASIA PACIFIC: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)           249

TABLE 248         ASIA PACIFIC: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)           249

TABLE 249         ASIA PACIFIC: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD BILLION) 250

TABLE 250         ASIA PACIFIC: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 250

11.7       ASIA PACIFIC: RECESSION IMPACT        250

11.7.1    JAPAN  251

11.7.1.1 Increasing government initiatives for improving quality of vaccines to drive market              251

TABLE 251         JAPAN: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)           251

TABLE 252         JAPAN: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)              252

TABLE 253         JAPAN: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)      252

TABLE 254         JAPAN: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)           253

TABLE 255         JAPAN: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           253

11.7.2    SOUTH KOREA 253

11.7.2.1 Strong government strategies for improved vaccine hubs to drive market 253

TABLE 256         SOUTH KOREA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)      254

TABLE 257         SOUTH KOREA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)           255

TABLE 258         SOUTH KOREA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)           255

TABLE 259         SOUTH KOREA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD BILLION) 256

TABLE 260         SOUTH KOREA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 256

11.7.3    CHINA  256

11.7.3.1 Growing investments in biotechnology sector to drive market    256

TABLE 261         CHINA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)           257

TABLE 262         CHINA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)              257

TABLE 263         CHINA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)      258

TABLE 264         CHINA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)           258

TABLE 265         CHINA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           259

11.7.4    INDIA   259

11.7.4.1 Increasing government initiatives and development of new and improved vaccines to drive market    259

TABLE 266         INDIA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)           260

TABLE 267         INDIA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)              260

TABLE 268         INDIA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)      261

TABLE 269         INDIA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)           261

TABLE 270         INDIA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           262

11.7.5    REST OF ASIA PACIFIC  262

TABLE 271         REST OF ASIA PACIFIC: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)           263

TABLE 272         REST OF ASIA PACIFIC: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION) 263

TABLE 273         REST OF ASIA PACIFIC: VACCINES MARKET, BY DISEASE INDICATION,  2021–2028 (USD BILLION)            264

TABLE 274         REST OF ASIA PACIFIC: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD BILLION) 264

TABLE 275         REST OF ASIA PACIFIC: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           265

11.8       LATIN AMERICA             265

TABLE 276         LATIN AMERICA: VACCINES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 265

TABLE 277         LATIN AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)      266

TABLE 278         LATIN AMERICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)           266

TABLE 279         LATIN AMERICA: VACCINES MARKET, BY DISEASE INDICATION,  2021–2028 (USD BILLION)            267

TABLE 280         LATIN AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD BILLION) 267

TABLE 281         LATIN AMERICA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 268

11.9       LATIN AMERICA: RECESSION IMPACT   268

11.9.1    BRAZIL 268

11.9.1.1 Rising focus on immunization programs by government and non-government bodies to drive market       268

TABLE 282         BRAZIL: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 269

TABLE 283         BRAZIL: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)           269

TABLE 284         BRAZIL: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)      270

TABLE 285         BRAZIL: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)           270

TABLE 286         BRAZIL: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           271

11.9.2    MEXICO             271

11.9.2.1 Presence of well-trained health professionals and ethnically varied population base for clinical trials to drive market       271

TABLE 287         MEXICO: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 272

TABLE 288         MEXICO: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)           272

TABLE 289         MEXICO: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)      273

TABLE 290        MEXICO: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)           273

TABLE 291         MEXICO: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           274

11.9.3    REST OF LATIN AMERICA          274

TABLE 292         REST OF LATIN AMERICA: VACCINES MARKET, BY TECHNOLOGY,  2021–2028 (USD BILLION)        275

TABLE 293         REST OF LATIN AMERICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)      275

TABLE 294         REST OF LATIN AMERICA: VACCINES MARKET, BY DISEASE INDICATION,  2021–2028 (USD BILLION)            276

TABLE 295         REST OF LATIN AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD BILLION) 276

TABLE 296         REST OF LATIN AMERICA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           277

11.10     MIDDLE EAST & AFRICA             277

11.10.1  MIDDLE EAST  277

11.10.1.1             Increasing prevalence of infectious diseases to drive market       277

TABLE 297         MIDDLE EAST: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION)      278

TABLE 298         MIDDLE EAST: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)           278

TABLE 299         MIDDLE EAST: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)           279

TABLE 300         MIDDLE EAST: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD BILLION) 279

TABLE 301         MIDDLE EAST: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION) 280

11.10.2  AFRICA 280

11.10.2.1             Availability of funds and grants from developed economies to drive market   280

TABLE 302         AFRICA: VACCINES MARKET, BY TECHNOLOGY, 2021–2028 (USD BILLION) 280

TABLE 303         AFRICA: VACCINES MARKET, BY TYPE, 2021–2028 (USD BILLION)           281

TABLE 304         AFRICA: VACCINES MARKET, BY DISEASE INDICATION, 2021–2028 (USD BILLION)      282

TABLE 305         AFRICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)           282

TABLE 306         AFRICA: VACCINES MARKET, BY END USER, 2021–2028 (USD BILLION)           283

11.10.3  MIDDLE EAST & AFRICA: RECESSION IMPACT   283

12          COMPETITIVE LANDSCAPE       284

12.1       INTRODUCTION            284

12.2       KEY STRATEGIES/RIGHT TO WIN           284

12.3       STRATEGIES OF KEY PLAYERS IN VACCINES MARKET   284

TABLE 307         STRATEGIES ADOPTED BY MAJOR PLAYERS IN VACCINES MARKET            284

12.4       REVENUE SHARE ANALYSIS       287

FIGURE 34         REVENUE SHARE ANALYSIS, 2020–2022  287

12.5       MARKET SHARE ANALYSIS         287

FIGURE 35         MARKET SHARE ANALYSIS OF MAJOR PLAYERS IN VACCINES MARKET, 2022  288

TABLE 308         DEGREE OF COMPETITION: VACCINES MARKET            288

12.6       COMPANY EVALUATION MATRIX          289

12.6.1    STARS  289

12.6.2    EMERGING LEADERS    289

12.6.3    PERVASIVE PLAYERS     289

12.6.4    PARTICIPANTS 290

FIGURE 36         COMPANY EVALUATION MATRIX, 2022 290

12.6.5    COMPANY FOOTPRINT 291

12.6.5.1 Product footprint 291

12.6.5.2 Regional footprint              292

12.7       START-UP/SME EVALUATION MATRIX 293

12.7.1    PROGRESSIVE COMPANIES       293

12.7.2    RESPONSIVE COMPANIES          293

12.7.3    DYNAMIC COMPANIES 293

12.7.4    STARTING BLOCKS       294

FIGURE 37         START-UP/SME EVALUATION MATRIX, 2022      294

12.7.5    COMPETITIVE BENCHMARKING            295

TABLE 309         DETAILED LIST OF KEY START-UPS/SMES         295

TABLE 310         TECHNOLOGY AND REGIONAL BENCHMARKING FOR START-UPS/SMES         295

12.8       COMPETITIVE SCENARIOS AND TRENDS           296

12.8.1    KEY PRODUCT LAUNCHES AND APPROVALS    296

TABLE 311         KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–SEPTEMBER 2023           296

12.8.2    KEY DEALS        297

TABLE 312         KEY DEALS, JANUARY 2021–SEPTEMBER 2023     297

12.8.3    OTHER KEY DEVELOPMENTS   298

TABLE 313         OTHER KEY DEVELOPMENTS, JANUARY 2021–SEPTEMBER 2023              298

13          COMPANY PROFILES    299

(Business overview, Products/Services/Solutions offered, Recent Developments, MNM view)*

13.1       KEY PLAYERS   299

13.1.1    PFIZER INC.       299

TABLE 314         PFIZER INC.: COMPANY OVERVIEW       299

FIGURE 38         PFIZER INC.: COMPANY SNAPSHOT (2022)         300

13.1.2    MERCK & CO., INC.         305

TABLE 315         MERCK & CO., INC.: COMPANY OVERVIEW         305

FIGURE 39         MERCK & CO. INC.: COMPANY SNAPSHOT (2022)            306

13.1.3    GSK PLC            310

TABLE 316         GSK PLC: COMPANY OVERVIEW             310

FIGURE 40         GSK PLC: COMPANY SNAPSHOT (2022) 311

13.1.4    SANOFI 317

TABLE 317         SANOFI: COMPANY OVERVIEW 317

FIGURE 41         SANOFI: COMPANY SNAPSHOT (2022)   318

13.1.5    CSL       322

TABLE 318         CSL: COMPANY OVERVIEW       322

FIGURE 42         CSL: COMPANY SNAPSHOT (2022)          323

13.1.6    EMERGENT       327

TABLE 319         EMERGENT: COMPANY OVERVIEW       327

FIGURE 43         EMERGENT: COMPANY SNAPSHOT (2022)          328

13.1.7    JOHNSON & JOHNSON SERVICES, INC.  330

TABLE 320         JOHNSON & JOHNSON SERVICES INC.: COMPANY OVERVIEW              330

FIGURE 44         JOHNSON & JOHNSON SERVICES INC: COMPANY SNAPSHOT (2022)   331

13.1.8    ASTRAZENECA 333

TABLE 321         ASTRAZENECA: COMPANY OVERVIEW  333

FIGURE 45         ASTRAZENECA: COMPANY SNAPSHOT (2022)    334

13.1.9    SERUM INSTITUTE OF INDIA PVT., LTD.             336

TABLE 322         SERUM INSTITUTE OF INDIA PVT., LTD.: COMPANY OVERVIEW        336

13.1.10  BAVARIAN NORDIC       341

TABLE 323         BAVARIAN NORDIC: COMPANY OVERVIEW        341

FIGURE 46         BAVARIAN NORDIC: COMPANY SNAPSHOT (2022)          341

13.1.11  MITSUBISHI TANABE PHARMA CORPORATION 345

TABLE 324         MITSUBISHI TANABE PHARMA CORPORATION: COMPANY OVERVIEW        345

13.1.12  DAIICHI SANKYO COMPANY, LIMITED  347

TABLE 325         DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW              347

FIGURE 47         DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2022)   348

13.1.13  PANACEA BIOTEC         350

TABLE 326         PANACEA BIOTEC: COMPANY OVERVIEW          350

FIGURE 48         PANACEA BIOTEC: COMPANY SNAPSHOT (2022)            351

13.1.14  BIOLOGICAL E LIMITED            353

TABLE 327         BIOLOGICAL E LIMITED: COMPANY OVERVIEW             353

13.1.15  BHARAT BIOTECH         357

TABLE 328         BHARAT BIOTECH: COMPANY OVERVIEW         357

13.1.16  NOVAVAX         360

TABLE 329         NOVAVAX: COMPANY OVERVIEW          360

FIGURE 49         NOVAVAX, INC.: COMPANY SNAPSHOT (2022)   360

13.1.17  INOVIO PHARMACEUTICALS    363

TABLE 330         INOVIO PHARMACEUTICALS: COMPANY OVERVIEW     363

FIGURE 50         INOVIO PHARMACEUTICALS: COMPANY SNAPSHOT (2022)              363

13.2       OTHER PLAYERS           366

13.2.1    SINOVAC           366

13.2.2    INCEPTA PHARMACEUTICALS LTD.      367

13.2.3    VALNEVA SE     369

13.2.4    VBI VACCINES INC.        370

13.2.5    BIO FARMA       371

13.2.6    FSUE NPO MICROGEN  373

13.2.7    ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.        374

13.2.8    INDIAN IMMUNOLOGICALS LIMITED   375

*Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

14          APPENDIX         376

14.1       DISCUSSION GUIDE      376

14.2       KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL             380

14.3       CUSTOMIZATION OPTIONS      382

14.4       RELATED REPORTS       382

14.5       AUTHOR DETAILS         383